HomeCompareGHVNF vs ABBV

GHVNF vs ABBV: Dividend Comparison 2026

GHVNF yields 1139.80% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 GHVNF wins by $59508396.19M in total portfolio value
10 years
GHVNF
GHVNF
● Live price
1139.80%
Share price
$0.18
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$59508396.29M
Annual income
$50,749,619,693,725.52
Full GHVNF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — GHVNF vs ABBV

📍 GHVNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodGHVNFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, GHVNF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
GHVNF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

GHVNF
Annual income on $10K today (after 15% tax)
$96,882.66/yr
After 10yr DRIP, annual income (after tax)
$43,137,176,739,666.70/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, GHVNF beats the other by $43,137,176,718,610.69/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of GHVNF + ABBV for your $10,000?

GHVNF: 50%ABBV: 50%
100% ABBV50/50100% GHVNF
Portfolio after 10yr
$29754198.20M
Annual income
$25,374,809,859,248.64/yr
Blended yield
85.28%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

GHVNF
No analyst data
Altman Z
19.4
Piotroski
1/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

GHVNF buys
0
ABBV buys
0
No recent congressional trades found for GHVNF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricGHVNFABBV
Forward yield1139.80%3.06%
Annual dividend / share$2.00$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.6%
Portfolio after 10y$59508396.29M$102.3K
Annual income after 10y$50,749,619,693,725.52$24,771.77
Total dividends collected$58850727.64M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: GHVNF vs ABBV ($10,000, DRIP)

YearGHVNF PortfolioGHVNF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$124,680$113,979.60$11,550$430.00+$113.1KGHVNF
2$1,461,532$1,328,124.33$13,472$627.96+$1.45MGHVNF
3$16,113,998$14,550,159.21$15,906$926.08+$16.10MGHVNF
4$167,168,715$149,926,737.17$19,071$1,382.55+$167.15MGHVNF
5$1,632,477,549$1,453,607,023.79$23,302$2,095.81+$1632.45MGHVNF
6$15,013,223,088$13,266,472,110.31$29,150$3,237.93+$15013.19MGHVNF
7$130,088,705,138$114,024,556,434.55$37,536$5,121.41+$130088.67MGHVNF
8$1,062,574,495,588$923,379,581,089.72$50,079$8,338.38+$1062574.45MGHVNF
9$8,185,772,521,991$7,048,817,811,712.23$69,753$14,065.80+$8185772.45MGHVNF
10$59,508,396,292,256$50,749,619,693,725.52$102,337$24,771.77+$59508396.19MGHVNF

GHVNF vs ABBV: Complete Analysis 2026

GHVNFStock

GoldHaven Resources Corp., a junior exploration company, engages in acquiring, exploring, and developing mineral properties in Canada and Chile. It focuses on exploring gold, copper, and silver deposits located in the Maricunga Gold Belt of northern Chile consisting of Coya, Rio Loa, Alicia, Condor, Jacqueline, Valle, and Roma projects. The company was formerly known as Altum Resource Corp. and changed its name to GoldHaven Resources Corp. in July 2020. GoldHaven Resources Corp. was incorporated in 2019 and is headquartered in Vancouver, Canada.

Full GHVNF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this GHVNF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

GHVNF vs SCHDGHVNF vs JEPIGHVNF vs OGHVNF vs KOGHVNF vs MAINGHVNF vs JNJGHVNF vs MRKGHVNF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.